BioTaiwan, June 28-July 2 2017
Omixon will be represented by our distributor, TBG at the upcoming BioTaiwan meeting in late June. Visit the official website here…
Human Leukocyte Antigen as a Critical Biomarker for the Adoption of Novel Immunotherapies of Cancer
– Written by Attila Bérces (Founder and Chairman, Omixon) While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation is still the dominant driver for the clinical HLA typing market. A new therapeutic paradigm in cancer...
High-throughput Automation of Holotype HLA in Routine HLA Genotyping at the EFI Annual Meeting 2017
Omixon announce today that Holotype HLA™ and other Omixon products will be featured in 12 poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) in Mannheim, Germany. Additionally, Omixon’s Lunch Symposium on Wednesday will focus on Automated HLA Typing by...
HKSHI, June 23-24 2017
Omixon is attending this year’s HKSHI Conference in Hong Kong. Contact us to schedule a meeting with the team. For more information, visit the HKSHI website here…
Omixon’s Developers Attended the SMRTLeiden Meeting 2017
After last year’s success the second SMRTLeiden Meeting was held between May 2nd and 4th, at Leiden University Medical Center, Leiden, Netherlands. The conference included two events: the SMRT Scientific Symposium and the second European SMRT Informatics Developers Meeting. The two-day long Scientific Symposium featured presentations from key experts...
